Variable inhibitory effect of herbal supplements of different brands on human P450 CYP1A2

EXCLI Journal

Volumn 11, Issue , 2012, Pages 7-19

  Wanwimolruk, Sompon ^a   Prachayasittikul, Virapong ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Black cohosh; CYP1A2; Dietary supplements; Drug interaction; Ginseng; Grape seed extract; Green tea extract

Indexed keywords

ACTION LABS; CIMICIFUGA RACEMOSA EXTRACT; CYTOCHROME P450 1A2; ETHOXYRESORUFIN; GINSENG EXTRACT; GRAPE SEED EXTRACT; GREEN TEA EXTRACT; HERBAL PLUS; IMPERIAL ELIXIR; LOMA LINDA MARKET; NATURAL BRAND; NATURE'S FINGERPRINT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESORUFIN; SOLARAYS; SPRING VALLEY; UNCLASSIFIED DRUG; WALGREENS FINEST NATURAL;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; LIVER MICROSOME; SUPPLEMENTATION;

EID: 84867617683     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Agarwal C, Singh RP, Agarwal R. Grape seed extract induces apoptotic death of hu-man prostate carcinoma DU145 cells via caspases activation accompanied by dissi-pation of mitochondrial membrane potential and cytochrome C reductase. Carcinogene-sis 2002;23:1869-76.
2. Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003;43:643-8.
3. Anger DL, Petre MA, Crankshaw DJ. Hete-roactivation of cytochrome P450 1A1 by teas and tea polyphenols. Br J Pharmacol 2005;145:926-33.
4. Bagchi D, Garg A, Krohn RL, Bagchi M, Tran MX, Stohs SJ. Oxygen free radical scavenging abilities of vitamin C and E, and a grape seed proanthocyanidin extract in vitro. Res Commun Mol Pathol Pharma-col 1997;95:179-89.
5. Bagchi D, Garg A, Krohn RL, Bagchi M, Bagchi DJ, Balmoori J et al. Protective ef-fects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macro-phage activation in mice. Gen Pharmacol 1998;30:771-6.
6. Blumenthal M. Herb sales down 15 percent in mainstream market. Herbalgram 2001; 51:69.
7. Bothe H, Gassmann K, Götz C, Fritsche E, Abel J, Haarmann-Stemmann T. Epigallo-catechin-3-gallate does not affect the activi-ty of enzymes involved in metabolic activa-tion and cellular excretion of benzo[a]py-rene in human colon carcinoma cells. Toxi-col Lett 2011;203:258-64.
8. Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT. Cytochrome P450 specifici-ties of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 1994;48:923-36.
9. Cabrera C, Artacho R, Gimez R. Beneficial efforts of green tea-a review. J Am Coll Nutr 2006;25:79-99.
10. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR, Dou QP. Dietary fla-vonoids as proteasome inhibitors and apop-tosis inducers in human leukemia cells. Biochem Pharmacol 2005;69:1421-32.
11. Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM et al. Effects of repeated green tea catechin administra-tion on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 2006;15:2473-6.
12. Cui J, Garle M, Eneroth P, Bjorkem I. What do commercial ginseng preparations con-tain? Lancet 1994;344:134.
13. Dhawan A, Anderson D, de Pascual-Teresa S, Santos-Buelga C, Clifford MN, Ioan-nides C. Evaluation of the antigenotoxic potential of monomeric and dimeric fla-vanols, and black tea polyphenols against heterocyclic amine-induced DNA damage in human lymphocytes using the Comet as-say. Mutat Res 2002;515:39-56.
14. Draves AH, Walker SE. Analysis of the hy-pericin and pseudohypericin content of commercially available St. John's wort preparations. Can J Clin Pharmacol 2003; 10:114-8.
15. Etheridge AS, Black SR, Patel PR, So J, Mathews JM. An in vitro evaluation of cy-tochrome P450 inhibition and P-gly-coprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 2007;73:731-41.
16. Foster BC, Arnason JT, Briggs CJ. Natural health products and drug disposition. Annu Rev Pharmacol Toxicol 2005;45:203-96.
17. Good Housekeeping Institute. New Good Housekeeping Institute study finds drastic discrepancy in potencies of popular herbal supplements. Consumer Safety Symposium on Dietary Supplements and Herbs, New York City, New York, March 3, 1998 (News release).
18. Green GA, Catlin DH, Starcevic B. Analy-sis of over-the-counter dietary supplements. Clin J Sport Med 2001;11:254-9.
19. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17.
20. Gurley BJ, Gardner SF, Hubbard MA. Con-tent versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm 2000;57:963-9.
21. Gurley BJ, Gardner SF, Hubbard MA, Wil-liams DK, Gentry WB, Khan IA et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 pheno-types. Clin Pharmacol Ther 2005a;77:415-26.
22. Gurley BJ, Gardner SF, Hubbard MA, Wil-liams DK, Gentry WB, Cui Y et al. Clinical assessment of effects of botanical supple-mentation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Penax ginseng and Ginkgo biloba. Drugs Aging 2005b;22:525-39.
23. Haller CA, Duan M, Benowitz NL, Jacob P III. Concentrations of ephedra alkaloids and caffeine in commercial dietary supple-ments. J Anal Toxicol 2004;28:145-51.
24. Hamburger M, Webner C, Benthin B. Cy-cloartane glycosides from Cimicifuga rac-emosa. Pharm Pharmacol Lett 2001;11:98-100.
25. Hanioka N, Tatarazako N, Jinno H, Arizono T, Ando M. Determination of cytochrome P450 1A activities in mammalian liver mi-crosomes by high-performance liquid chro-matography with fluorescence detection. J Chromatogr B 2000;744:399-406.
26. Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001; 73:1101-6.
27. Helms S. Cancer prevention and therapeu-tic: Panax Ginseng. Altern Med Rev 2004; 9:259-74.
28. Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM. Ef-fects of ginseng components on c-DNA-expressed cytochrome P450 enzyme cata-lytic activity. Life Sci 1999;65:PL209-14.
29. Henning SM, Aronson W, Niu Y, Conde F, Lee NH, Seeram NP et al. Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. J Nutr 2006;136:1839-43.
30. Huang Y, Jiang B, Nuntanakorn P, Kennel-ly EJ, Shord S, Lawal TO et al. Fukinolic acid derivatives and triterpene glycosides from black cohosh inhibit CYP isozymes, but are not cytotoxic to Hep-G2 cells in vitro. Curr Drug Saf 2010;5:118-24.
31. Jang EH, Choi JY, Park CS, Lee SK, Kim CE, Park HJ et al. Effects of green tea ex-tract administration on the pharmacokinet-ics of clozapine in rats. J Pharm Pharmacol 2005;57:311-6.
32. Kowalczyk MC, Walaszek Z, Kowalczyk P, Kinjo T, Hanausek M, Slaga TJ. Differ-ential effects of several phytochemicals and their derivatives on murine keratinocytes in vitro and in vivo: implications for skin can-cer prevention. Carcinogenesis 2009;30: 1008-15.
33. Lautraite S, Musonda AC, Doehmer J, Ed-wards GO, Chipman JK. Flavonoids inhibit genetic toxicity produced by carcinogens in cells expressing CYP1A2 and CYP1A1. Mutagenesis 2002;17:45-53.
34. Liu R, Qin M, Hang P, Liu Y, Zhang Z, Liu G. Effects of Panax notoginseng Saponins on the activities of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 in rats in vivo. Phy-tother Res 2011; doi:10.1002/ptr.3688. [Epub ahead of print].
35. Maffei FR, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E et al. Procya-nidins from Vitis vinifera seeds protect rab-bit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta Med 1996;62:495-502.
36. Maliakal P, Sankpal UT, Basha R, Maliakal C, Ledford A, Wanwimolruk S. Relevance of drug metabolizing enzyme activity mod-ulation by tea polyphenols in the inhibition of esophageal tumorigenesis. Med Chem 2011;7:480-7.
37. Murray BP, Edwards RJ, Murray S, Single-ton AM, Davies DS, Boobis AR. Human hepatic CYP1A1 and CYP1A2 content, de-termined with specific anti-peptide antibod-ies, correlates with the mutagenic activation of PhIP. Carcinogenesis 1993;14:589-92.
38. Netsch MI, Gutmann H, Schmidlin CB, Aydogan C, Drewe J. Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med 2006;72:514-20.
39. Pang X, Cheng J, Krausz KW, Guo DA, Gonzalez FJ. Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xeno-biotica 2011;41:112-23.
40. Pierce JP, Faerber S, Wright FA, Rock CL, Newman V, Flatt SW et al. A randomized trial of the effect of plant-based dietary pat-tern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) study. Contr Clin Trials 2002;23:728-56.
41. Richardson MA, Ramirez T, Palmer JL, Greisinger A, Singletary SE. Complemen-tary/alternative medicine use in a compre-hensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-14.
42. Rock CL, Newman VA, Neuhouser ML, Major J, Barnett MJ. Antioxidant supple-ment use in cancer survivors and the gen-eral population. J Nutr 2004;Suppl:3155S-6S.
43. Rockwell S, Liu Y, Higgin SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat 2005;90:233-9.
44. Sato M, Sato T, Izumo T, Amagasa T. Ge-netically high susceptibility of oral squa-mous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes. Oral Oncol 2000;36:267-71.
45. Sevior DK, Hokkanen J, Tolonen A, Abass K, Tursas L, Pelkonen O et al. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica 2010;40: 245-54.
46. Shi S, Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet 2012;51:77-104.
47. Singletary KW, Meline B. Effect of grape seed proanthocyanidins in colon aberrant crypts and breast tumors in a rat dual-organ tumor model. Nutr Cancer 2001;39:252-8.
48. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: Potential adverse reactions with an-ticancer drugs. J Clin Oncol 2004;22:2489-503.
49. Tsukamoto S, Aburatani M, Ohta T. Isola-tion of CYP3A4 inhibitors from the Black Cohosh (Cimicifuga racemosa). Evid Based Complement Alternat Med 2005;2:223-6.
50. Wanwimolruk S, Wong K, Wanwimolruk P. Variable inhibitory effect of commercial herbal supplements with different brands on human cytochrome P450 CYP3A4. Drug Metabol Drug Interact 2009;24:17-35.
51. Wargovich MJ. Colon cancer chemopre-vention with ginseng and other botanicals. J Korean Med Sci 2001;16(Suppl):S81-S86.
52. Wargovich MJ, Morris J, Brown V, Ellis J, Logothetis B, Weber R. Nutraceutical use in late-stage cancer. Cancer Metastasis Rev 2010;29:503-10.
53. Yang CS, Landau JM. Effects of tea con-sumption on nutrition and health. J Nutr 2000;130:2409-12.
54. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Phar-macol Toxicol 2002;42:25-54.
55. Yang CS, Sang S, Lambert JD, Hou Z, Ju J, Lu G. Possible mechanisms of the cancer-preventive activities of green tea. Mol Nutr Food Res 2006;50:170-5.
56. Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S. Evidence for an involvement of human CYP3A in the 3-hydroxylation of quinine. Br J Clin Phar-macol 1997;43:245-52.
57. Zhao J, Wang J, Chen Y, Agarwal R. Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidins B5-3′-gallate as the most effective antioxi-dant constituent. Carcinogenesis 1999;20: 1737-45.